慢性型肝炎感染中的初级干扰素耐药性和治疗反应:试点研究
Lancet (London, England)
|October 25, 2001
概括
单次干扰素剂量后的早期病毒载量下降预测慢性肝炎C病毒基因型1 (HCV-1) 患者的治疗成功. 如果下降到70%以下,则表明可能对组合疗法没有反应.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 药理动力学是什么 药理动力学
背景情况:
- 慢性肝炎C病毒基因型1 (HCV-1) 感染在标准干扰素和利巴维林治疗中具有较低的持续病毒学反应率 (30%).
- 预测治疗反应对于优化患者管理和治疗策略至关重要.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...


